COMP <GO>
XLO vs ONCY // GROSS PROFIT MARGIN
Xilio Therapeutics Inc. (NASDAQ) VS. Oncolytics Biotech Inc. (NASDAQ) • 15-METRIC TALLY: XLO 3
— ONCY 0
■ METRIC PARITY
LAST: $7.99 (-0.50%) • MKT CAP: $52.6M
gross-margins
—
LAST: $0.40 (-5.97%) • MKT CAP: $52.4M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XLO VS. ONCY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XLO | ONCY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.78% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | XLO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.4 | 21.1 | +20.30 | XLO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $52.6M | $52.4M | $127.1K | XLO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XLO REV | ONCY REV | XLO GROSS % | ONCY GROSS % | XLO FCF | ONCY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $43.8M | $80.4M | — | — | -$5.5M | -$20.1M |
| FY 2024 | $6.3M | $71.5M | — | — | -$18.4M | -$20.1M |
| FY 2023 | $221.6M | — | — | — | -$68.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XLO // BETA —
ONCY // BETA —